Title : The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.

Pub. Date : 2011 Dec

PMID : 22207908






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 MT-102, a novel anabolic/catabolic transforming agent, has a multi-functional effect upon three potential pharmacological targets in cancer cachexia, namely reduced catabolism through non-selective beta-blockade, reduced fatigue, and thermogenesis through central 5-HT1a antagonism and increased anabolism through partial beta-2 receptor agonism. Pindolol 5-hydroxytryptamine receptor 1A Homo sapiens